



**Device Proprietary Name:** 

OsteoMed OSA Rigid Internal

Fixation System

**Device Common Name:** 

Bone Plate

Classification Name:

Plate, Bone

Name of Submitter:

OsteoMed Corporation 3750 Realty Road

Addison, Texas 75001 Phone: (972) 241-3401 Fax: (972) 241-3449

Contact Person:

Dawn T. Holdeman

Date Prepared:

May 15, 2002

Summary:

This submission describes the OsteoMed OSA Rigid Internal Fixation System intended for use in a variety of pan facial indications. Specifically, this system is intended for selective trauma of the midface and craniofacial skeleton; craniofacial surgery; reconstructive procedures; and selective orthognathic surgery of the maxilla and mandible.

The OsteoMed OSA Rigid Internal Fixation System is comprised of various plates and screws. Plates, .8mm through 1.0mm thick, are provided in various shapes and sizes. Screws are provided in 1.6mm and 2.0mm diameter in lengths of 4.0mm through 8.0mm. Safety screws are 1.9mm and 2.4mm diameter. Depth gauges, screwdrivers, countersinks, pilot drills, and preparation instruments will also be a part of the system.

Equivalence for this device is based on similarities in intended use, material, design and operational principle to the Synthes 1.5mm/2.0mm Orthognathic Plates and Screws system (K980199), the KLS Martin Lindorf System (K944565), and the Leibinger Profil-O-Plastic, Titanium Implant System.

Due to the similarity of materials and design to both pre-enactment and post-enactment devices, OsteoMed believes that the OsteoMed OSA Rigid Internal Fixation System does not raise any new safety or effectiveness issues.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## AUG 0 8 2002

Ms. Dawn T. Holdeman Regulatory Affairs and Document Control OsteoMed Corporation 3750 Realty Road Addison, Texas 75001-4311

Re: K021618

Trade/Device Name: OSA Rigid Internal Fixation System

Regulation Number: 21 CFR 872.4760

Regulation Name: Bone Plate

Regulatory Class: II Product Code: JEY Dated: May 15, 2002 Received: May 16, 2002

## Dear Ms. Holdeman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal</u> Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Timothy A. Ulatowski

Director

Sincere

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## OsteoMed "Intended Use" Submission

510(k) Number: <u>K021618</u>	
Device Name:	OsteoMed OSA Rigid Internal Fixation System
Intended Use:	OsteoMed OSA Rigid Internal Fixation System is intended for a variety of pan facial indications Specifically, the system is intended for selective trauma of the midface and craniofacial skeleton craniofacial surgery; reconstructive procedures; and selective orthognathic surgery of the maxilla and mandible. Implants are single use only.
Concurrence of CDRH, Office of Device Evaluation (ODE)	
Prescription Use (Per 21 CFR 810.109)	Over-The Counter-Use (Optical Format 1-)
(Division of the control of the cont	Sion Sign-Off) ion of Anesthesiology, General Hospital, tion Control, Dental Devices  (3) Number: